You Position: Home > Paper
Expression of FLT3 and point mutation in tyrosine kinase domain in acute myeloid leukemia patients
( views:356, downloads:66 )
- Author:
- No author available
- Journal Title:
- JOURNAL OF LEUKEMIA & LYMPHOMA
- Issue:
- 1
- DOI:
- 10.3760/cma.j.issn.1009-9921.2007.01.002
- Key Word:
- FLT3基因;受体蛋白质酪氨酸激酶类;白血病,粒细胞,急性;CD135分子;点突变
Abstract： 目的 研究急性髓系白血病(AML)患者与正常人FMS样酷氨酸激酶3(FLT3)基因在骨髓中表达的差异以及FLT3基因酪氨酸激酶结构域(TKD)点突变与AML的关系.方法 将AML初治患者和正常人的骨髓分别用CD135抗体标记后,应用三色流式细胞术检测并分析;采用RT-PCR结合限制性内切酶酶切,检测30例AML初治患者FLT3基因的TKD点突变.结果 AML患者骨髓中CD135阳性率均＞20%,而正常人＜2%,二者差异有统计学意义(P＜0.05);另外,30例AML患者中3例存在FLT3-TKD点突变,阳性率为10%,其中2例化疗后完全缓解(CR),缓解率66.7%,其他27例非点突变患者化疗后完全缓解率为84%,二者比较差异无统计学意义(P＞0.05).结论 AML患者骨髓中FLT3基因表达显著高于正常人.AML患者FLT3-TKD点突变的阳性率为10%左右,FLT3-TKD点突变对患者化疗后CR率的影响有待进一步研究.
- [1]Y, Yamamoto,H, Kiyoi,Y, Nakano,etc.Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.[J].2001,97(8).
- [2]I, Rappold,B L, Ziegler,I, K?hler,etc.Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase.[J].1997,90(1).
- [3]Naoe T,Kiyoi H.Normal and oncogenic FLT3[J].2004,61(23).
- [4]F M, Abu-Duhier,A C, Goodeve,G A, Wilson,etc.Genomic structure of human FLT3: implications for mutational analysis.[J].2001,113(4).